This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyazaki, E.
Right arrow Articles by Bishai, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, E.
Right arrow Articles by Bishai, W. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1999, p. 85-89, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis

Eishi Miyazaki,1 Miki Miyazaki,1 Jong Min Chen,1 Richard E. Chaisson,2,3 and William R. Bishai1,2,3,*

Center for Tuberculosis Research, Departments of International Health2 and Molecular Microbiology and Immunology,1 Johns Hopkins School of Public Health, and Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine,3 Baltimore, Maryland 21205-2179

Received 3 August 1998/Returned for modification 1 September 1998/Accepted 20 October 1998

Moxifloxacin (BAY12-8039) is a new 8-methoxyquinolone shown to be active against Mycobacterium tuberculosis in vitro. We tested moxifloxacin for activity in mice against M. tuberculosis CSU93, a highly virulent, recently isolated clinical strain. The MIC of moxifloxacin for the CSU93 strain was 0.25 µg/ml. The serum moxifloxacin concentration after oral administration in mice peaked within 0.25 h, reaching 7.8 µg/ml with doses of 100 mg/kg of body weight; the maximum concentration and the analysis of the area under the concentration-time curve revealed dose dependency. When mice were infected with a sublethal inoculum of mycobacteria and then treated with moxifloxacin at 100 mg/kg per day for 8 weeks, the log10 CFU counts in the organs of treated mice were significantly lower than those for the control group (0.6 ± 0.2 versus 5.6 ± 0.3 in the lungs and 1.5 ± 0.7 versus 4.9 ± 0.5 in the spleens, respectively; P < 0.001 in both organs). The effectiveness of moxifloxacin monotherapy was comparable to that seen in mice receiving isoniazid alone. Combination therapy with moxifloxacin plus isoniazid was superior to that with moxifloxacin or with isoniazid alone in reducing bacillary counts in the organs studied. Using a sensitive broth-passage subculture method, we demonstrated that 8 weeks of treatment with moxifloxacin (100 mg/kg per day) or with moxifloxacin plus isoniazid (100 mg/kg and 25 mg/kg, respectively, per day) sterilized the lungs in seven of eight and in eight of eight mice, respectively. Among surviving bacilli isolated from animals infected with a high-titer inoculum and treated for 7 weeks with low-dose moxifloxacin (20 mg/kg per day), breakthrough resistance to moxifloxacin was not observed. These results indicate that moxifloxacin is highly effective in reducing M. tuberculosis infection in mice and has activity comparable to that of isoniazid. Combination therapy with moxifloxacin and isoniazid was highly effective, suggesting that moxifloxacin may be useful in multiple-drug regimens for human tuberculosis.

* Corresponding author. Mailing address: Center for Tuberculosis Research, Johns Hopkins School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205-2179. Phone: (410) 955-3507. Fax: (410) 614-8173. E-mail: wbishai{at}jhsph.edu.

Antimicrobial Agents and Chemotherapy, January 1999, p. 85-89, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Woolhiser, L. K., Hoff, D. R., Marietta, K. S., Orme, I. M., Lenaerts, A. J. (2009). Testing of Experimental Compounds in a Relapse Model of Tuberculosis Using Granulocyte-Macrophage Colony-Stimulating Factor Gene-Disrupted Mice. Antimicrob. Agents Chemother. 53: 306-308 [Abstract] [Full Text]  
  • Pardillo, F. E. F., Burgos, J., Fajardo, T. T., Cruz, E. D., Abalos, R. M., Paredes, R. M. D., Andaya, C. E. S., Gelber, R. H. (2008). Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy. Antimicrob. Agents Chemother. 52: 3113-3117 [Abstract] [Full Text]  
  • Almeida, D., Nuermberger, E., Tyagi, S., Bishai, W. R., Grosset, J. (2007). In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 51: 4261-4266 [Abstract] [Full Text]  
  • Huitric, E., Verhasselt, P., Andries, K., Hoffner, S. E. (2007). In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor. Antimicrob. Agents Chemother. 51: 4202-4204 [Abstract] [Full Text]  
  • Wang, J.-Y., Lee, L.-N., Lai, H.-C., Wang, S.-K., Jan, I-S., Yu, C.-J., Hsueh, P.-R., Yang, P.-C. (2007). Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59: 860-865 [Abstract] [Full Text]  
  • Yew, W. W., Leung, C. C. (2007). Update in Tuberculosis 2006. Am. J. Respir. Crit. Care Med. 175: 541-546 [Full Text]  
  • Malik, M., Drlica, K. (2006). Moxifloxacin Lethality against Mycobacterium tuberculosis in the Presence and Absence of Chloramphenicol.. Antimicrob. Agents Chemother. 50: 2842-2844 [Abstract] [Full Text]  
  • Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., Vernon, A., Chaisson, R. E., and the Tuberculosis Trials Consortium, (2006). Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 174: 331-338 [Abstract] [Full Text]  
  • Schwartz, Y. S., Dushkin, M. I., Vavilin, V. A., Melnikova, E. V., Khoschenko, O. M., Kozlov, V. A., Agafonov, A. P., Alekseev, A. Y., Rassadkin, Y., Shestapalov, A. M., Azaev, M. S., Saraev, D. V., Filimonov, P. N., Kurunov, Y., Svistelnik, A. V., Krasnov, V. A., Pathak, A., Derrick, S. C., Reynolds, R. C., Morris, S., Blinov, V. M. (2006). Novel Conjugate of Moxifloxacin and Carboxymethylated Glucan with Enhanced Activity against Mycobacterium tuberculosis.. Antimicrob. Agents Chemother. 50: 1982-1988 [Abstract] [Full Text]  
  • Gruppo, V., Johnson, C. M., Marietta, K. S., Scherman, H., Zink, E. E., Crick, D. C., Adams, L. B., Orme, I. M., Lenaerts, A. J. (2006). Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis.. Antimicrob. Agents Chemother. 50: 1245-1250 [Abstract] [Full Text]  
  • Nuermberger, E., Tyagi, S., Williams, K. N., Rosenthal, I., Bishai, W. R., Grosset, J. H. (2005). Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am. J. Respir. Crit. Care Med. 172: 1452-1456 [Abstract] [Full Text]  
  • Veziris, N., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V. (2005). Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. Antimicrob. Agents Chemother. 49: 4015-4019 [Abstract] [Full Text]  
  • Ginsburg, A. S., Sun, R., Calamita, H., Scott, C. P., Bishai, W. R., Grosset, J. H. (2005). Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model. Antimicrob. Agents Chemother. 49: 3977-3979 [Abstract] [Full Text]  
  • Malik, M., Lu, T., Zhao, X., Singh, A., Hattan, C. M., Domagala, J., Kerns, R., Drlica, K. (2005). Lethality of Quinolones against Mycobacterium smegmatis in the Presence or Absence of Chloramphenicol. Antimicrob. Agents Chemother. 49: 2008-2014 [Abstract] [Full Text]  
  • Steward, J., Piercy, T., Lever, M. S., Nelson, M., Simpson, A. J. H., Brooks, T. J. G. (2005). Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection. J Antimicrob Chemother 55: 523-527 [Abstract] [Full Text]  
  • Ginsburg, A. S., Lee, J., Woolwine, S. C., Grosset, J. H., Hamzeh, F. M., Bishai, W. R. (2005). Modeling In Vivo Pharmacokinetics and Pharmacodynamics of Moxifloxacin Therapy for Mycobacterium tuberculosis Infection by Using a Novel Cartridge System. Antimicrob. Agents Chemother. 49: 853-856 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R. J., Vernon, A. A., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 170: 1131-1134 [Abstract] [Full Text]  
  • Parrish, N. M., Ko, C. G., Hughes, M. A., Townsend, C. A., Dick, J. D. (2004). Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J Antimicrob Chemother 54: 722-729 [Abstract] [Full Text]  
  • Gosling, R., Gillespie, S., Pletz, M. W. R., Lode, H. (2004). Moxifloxacin Treatment of Tuberculosis. Antimicrob. Agents Chemother. 48: 3642-3643 [Full Text]  
  • Steward, J., Lever, M. S., Simpson, A. J. H., Sefton, A. M., Brooks, T. J. G. (2004). Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J Antimicrob Chemother 54: 95-99 [Abstract] [Full Text]  
  • Chan, E. D., Laurel, V., Strand, M. J., Chan, J. F., Huynh, M.-L. N., Goble, M., Iseman, M. D. (2004). Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 1103-1109 [Abstract] [Full Text]  
  • Geiman, D. E., Kaushal, D., Ko, C., Tyagi, S., Manabe, Y. C., Schroeder, B. G., Fleischmann, R. D., Morrison, N. E., Converse, P. J., Chen, P., Bishai, W. R. (2004). Attenuation of Late-Stage Disease in Mice Infected by the Mycobacterium tuberculosis Mutant Lacking the SigF Alternate Sigma Factor and Identification of SigF-Dependent Genes by Microarray Analysis. Infect. Immun. 72: 1733-1745 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
  • Gosling, R. D., Uiso, L. O., Sam, N. E., Bongard, E., Kanduma, E. G., Nyindo, M., Morris, R. W., Gillespie, S. H. (2003). The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 168: 1342-1345 [Abstract] [Full Text]  
  • Veziris, N., Truffot-Pernot, C., Aubry, A., Jarlier, V., Lounis, N. (2003). Fluoroquinolone-Containing Third-Line Regimen against Mycobacterium tuberculosis In Vivo. Antimicrob. Agents Chemother. 47: 3117-3122 [Abstract] [Full Text]  
  • Yew, W. W., Chan, C. K., Leung, C. C., Chau, C. H., Tam, C. M., Wong, P. C., Lee, J. (2003). Comparative Roles of Levofloxacin and Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis: Preliminary Results of a Retrospective Study From Hong Kong. Chest 124: 1476-1481 [Abstract] [Full Text]  
  • Lessnau, K.-D. K. L., Qarah, S. (2003). Multidrug-Resistant Tuberculosis in Pregnancy: Case Report and Review of the Literature. Chest 123: 953-956 [Abstract] [Full Text]  
  • Iseman, M.D. (2002). Tuberculosis therapy: past, present and future. Eur Respir J 20: 87S-94s [Abstract] [Full Text]  
  • Yoshimatsu, T., Nuermberger, E., Tyagi, S., Chaisson, R., Bishai, W., Grosset, J. (2002). Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis. Antimicrob. Agents Chemother. 46: 1875-1879 [Abstract] [Full Text]  
  • Alvirez-Freites, E. J., Carter, J. L., Cynamon, M. H. (2002). In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46: 1022-1025 [Abstract] [Full Text]  
  • Lounis, N., Bentoucha, A., Truffot-Pernot, C., Ji, B., O'Brien, R. J., Vernon, A., Roscigno, G., Grosset, J. (2001). Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice. Antimicrob. Agents Chemother. 45: 3482-3486 [Abstract] [Full Text]  
  • Tuberculosis Drug Screening Program, (2001). Search for New Drugs for Treatment of Tuberculosis. Antimicrob. Agents Chemother. 45: 1943-1946 [Full Text]  
  • GILLESPIE, S. H., MORRISSEY, I., EVERETT, D. (2001). A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 50: 565-570 [Abstract] [Full Text]  
  • O'BRIEN, R. J., NUNN, P. P. (2001). The Need for New Drugs against Tuberculosis . Obstacles, Opportunities, and Next Steps. Am. J. Respir. Crit. Care Med. 163: 1055-1058 [Full Text]  
  • Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., Young, L. S. (2001). Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45: 217-222 [Abstract] [Full Text]  
  • Kawakami, K., Namba, K., Tanaka, M., Matsuhashi, N., Sato, K., Takemura, M. (2000). Antimycobacterial Activities of Novel Levofloxacin Analogues. Antimicrob. Agents Chemother. 44: 2126-2129 [Abstract] [Full Text]  
  • Manabe, Y. C., Saviola, B. J., Sun, L., Murphy, J. R., Bishai, W. R. (1999). Attenuation of virulence in Mycobacterium tuberculosis expressing a constitutively active iron repressor. Proc. Natl. Acad. Sci. USA 96: 12844-12848 [Abstract] [Full Text]  
  • Miyazaki, E., Chaisson, R. E., Bishai, W. R. (1999). Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis. Antimicrob. Agents Chemother. 43: 2126-2130 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»